# Junta clínica — PT-pseudo_aed2e170b8e6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_aed2e170b8e6",
  "pid": "PT-pseudo_aed2e170b8e6",
  "task": 1,
  "psa": 86.0,
  "age": 73,
  "months": 1,
  "pirads": "5",
  "psad": 2.306,
  "psav": 14.92,
  "psap": 57.4,
  "vol": 37.29,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.9527162,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 86 ng/mL. PI-RADS 5. PSAD 2.31. Prostate volume 37 mL. DRE nodus. csPCa 0.95.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "84 kg",
    "height": "181 cm",
    "bmi": "25.6",
    "bp": "111/74 mmHg",
    "hr": "72 bpm",
    "smoking": "Non-smoker",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "12 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Specialist assessment required after confirmed malignancy and subsequent PSA elevation."
    },
    {
      "s": "History",
      "t": "A 73-year-old warehouse manager seeks specialist guidance following prolonged urological tracking. He is married and resides in an independent unit within a retirement community. He is a non-smoker. Lower urinary tract complaints remain minimal, yielding a 4/35 IPSS score. Despite significant anxiety surrounding invasive diagnostics, he requests thorough consultations. His medical history contains no comorbidities, and he takes no active medication, aside from a minor knee arthroscopy more than ten years ago and a recent dermatology check for actinic keratosis monitoring. He explicitly denies bone discomfort, unexplained weight reduction, or blood in the urine."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm; mobility: fixed; asymmetry: palpable nodus in the right lobe. The remaining abdominal and cardiovascular survey shows no anomalies. Vital signs record 111/74 mmHg with a steady pulse of 72 bpm. He demonstrates adequate perfusion and preserves standard functional capacity."
    }
  ],
  "occupation": "warehouse manager",
  "marital": "Married",
  "living": "Lives in retirement community (independent unit)",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Swimming 1x/week",
  "ipss": "IPSS score: 4/35 (mild LUTS)",
  "admin": "Patient anxious about procedures — allocate extra consult time.",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_aed2e170b8e6
Task: 1

Encounter: Urology - outpatient on 12 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 73-year-old male
  - PSA: 86.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 2.306 ng/mL²
  - PSA velocity: 14.92 ng/mL/yr
  - Prior PSA: 57.4 ng/mL
  - Prostate volume: 37.29 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.9527162 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 86 ng/mL. PI-RADS 5. PSAD 2.31. Prostate volume 37 mL. DRE nodus. csPCa 0.95.

Vitals: weight 84 kg, height 181 cm, BMI 25.6, BP 111/74 mmHg, HR 72 bpm. Smoking: Non-smoker.

Chief complaint: Specialist assessment required after confirmed malignancy and subsequent PSA elevation.

History: A 73-year-old warehouse manager seeks specialist guidance following prolonged urological tracking. He is married and resides in an independent unit within a retirement community. He is a non-smoker. Lower urinary tract complaints remain minimal, yielding a 4/35 IPSS score. Despite significant anxiety surrounding invasive diagnostics, he requests thorough consultations. His medical history contains no comorbidities, and he takes no active medication, aside from a minor knee arthroscopy more than ten years ago and a recent dermatology check for actinic keratosis monitoring. He explicitly denies bone discomfort, unexplained weight reduction, or blood in the urine.

Physical examination: DRE — texture: firm; mobility: fixed; asymmetry: palpable nodus in the right lobe. The remaining abdominal and cardiovascular survey shows no anomalies. Vital signs record 111/74 mmHg with a steady pulse of 72 bpm. He demonstrates adequate perfusion and preserves standard functional capacity.

Patient info: warehouse manager; Married; Lives in retirement community (independent unit).
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Swimming 1x/week; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.43
  uncertainty  +/- 0.16 epistemic (95% band 0.12-0.73); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.93: PI-RADS 5, PSA 113.0, PSAD 2.61, age 67, DRE Nodus -> DEFER (clear). He wrote: "Patient has a verified PCa with PSA 113. Start treatment and do I PSMA-PET for further workup."
  2. distance 1.10: PI-RADS 5, PSA 187.0, PSAD 3.26, age 75, DRE Nodus -> BIOPSY (clear). He wrote: "Very High PSA. Most likely metastatic"
  3. distance 1.50: PI-RADS 5, PSA 190.0, PSAD 4.097, age 66, DRE Nodus -> DEFER (clear). He wrote: "Patient with a clear PCa diagnosis. Do PSMA-PET and start hormontreatment"

PRECEDENT: DEFER (weighted vote 0.34 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the risk-adapted matrix for biopsy based on PI-RADS score and PSA density. It states that a PSA-D cut-off of 0.15 ng/mL/cc is used to guide the decision to perform a biopsy.

"linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert-Structured's suggestion of no biopsy is based only on the panel variables, whereas the guideline mandates integrating the PI-RADS score and PSA density into a risk-adapted matrix. Expert-Cohort's criterion, which focuses on prior positive biopsy, is superseded by the guideline's requirement to use the risk matrix.

WHAT WE STILL NEED
The guideline requires the PSA density value to determine the risk category. The panel shows a PSA density of 2.306 ng/mL², which falls into the highest risk category (> 0.20 ng/mL/cc). The guideline requires the specific prior biopsy status to be known to apply the matrix correctly.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on applying the EAU risk matrix which requires knowing the prior biopsy status to interpret the PI-RADS and PSA density findings.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What was the prior biopsy result (Gleason/ISUP), surveillance protocol status, number/dates of biopsy sessions, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the GRADE of the prior positive biopsy?
  Q2. What is the status of the surveillance protocol and planned confirmatory biopsy?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Lesion size and zone: "spanning roughly 22 mm" in the "right mid-gland peripheral zone". Extraprostatic extension: "Capsular integrity remains intact with no seminal vesicle involvement". Comparison against an earlier study: "Re-assessment of established malignancy".
psa_trend
Serial PSA value trend: "rising" from "2.7" ng/mL at "Aug 2023" to "86.0" ng/mL at "Jan 2025".
previous_notes
Prior biopsy result: "positive". Surveillance protocol status: "warranting continued monitoring". Number/dates of biopsy sessions: "one". Planned treatment: "no immediate therapeutic actions were necessary".

WHAT I DID NOT OPEN
family-history of prostate cancer (anamnesis) because the previous notes already established the prior biopsy status and surveillance context.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 lesion in the right mid-gland.
Serial PSA trend is rising from 12.2 ng/mL to 86.0 ng/mL.

Findings that argue AGAINST sampling this patient now:
Prior biopsy result was positive.
Previous notes indicate "no immediate therapeutic actions were necessary".

WHERE THIS LEANS
The findings strongly suggest a high-risk scenario based on the EAU risk matrix, but the prior positive biopsy status complicates the decision.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 86.00 ng/mL over 3 points spanning 17 months; velocity +57.84 ng/mL per year; doubling time about 3 months.
PROJECTION at 6 months: 80.5 ng/mL, conformal 95% band 23.1-280.4.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.13 epistemic (95% band 0.21-0.73), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.43  ('discuss' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.47  ('discuss' tier, fusion_nolab)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.34  (k=3 precedents)
  EXPERT-COHORT      DEFER  (rule psa_ge_20)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).

Confidence the trace model expects here: clear. Weights it expects: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—address the moderator's questions by providing information on the lesion characteristics, PSA trajectory, and prior biopsy status.

ALIGNMENT WITH THE PANEL
The retrieved evidence is unclear regarding the panel's conclusion. The panel's answer of NO BIOPSY rests on the cohort criterion (PSA $\ge 20$ ng/mL), which is supported by the rising PSA trend (from 2.7 to 86.0 ng/mL) retrieved from the `psa_trend` document.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the GRADE of the prior positive biopsy? This information was not retrieved by the registrar.
Q2. What is the status of the surveillance protocol and planned confirmatory biopsy? This information was not retrieved by the registrar.

WHAT CARRIES WEIGHT, AND WHY
The PSA trend (rising from 2.7 to 86.0 ng/mL) is highly relevant as it directly supports the cohort criterion that fired the panel protocol. The prior biopsy result is critical for interpreting the risk matrix, which the EAU guideline requires.

MY SUGGESTION TO THE CHAIR
Given that the critical information regarding the prior biopsy grade and surveillance status remains unretrieved, the decision cannot be definitively made according to the EAU risk matrix. Therefore, the case is not ready for a final decision.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

Decision to defer biopsy for a 73-year-old man with PI-RADS 5, PSA 86.0 ng/mL, PSA density 2.306 and a prior biopsy status of 'Positive'. The panel protocol settled it by the rule 'cohort criterion (psa_ge_20)' (EXPERT-COHORT); It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy). The conference did not return a readable structured form, so this record was completed from the minute alone; no finding is asserted beyond the values in it.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
[completed by the deterministic fallback: the form did not validate]
